Coronary endothelial dysfunction in the hypertensive patient: From myocardial ischemia to heart failure

Journal of Human Hypertension

Volumn 11, Issue 1, 1997, Pages 45-49

  Burnett Jr , J C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Endothelium; Hormones; Peptides

Indexed keywords

ENDOTHELIN; NITRIC OXIDE;

ARTERY ENDOTHELIUM; ARTERY TONE; ATHEROSCLEROSIS; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CORONARY ARTERY; ESSENTIAL HYPERTENSION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION;

EID: 0030932648     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000400     Document Type: Conference Paper

References (28)

1. Florey HW. The endothelial cell. Br Med J 1966; 2: 487-489.
2. Lerman A et al. Endothelin: A new cardiovascular regulatory peptide. Mayo Clin Proc 1990; 65: 1441-1455.
3. Furchgott RF, Zawadski JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 188: 373-376.
4. Luscher TF, Boulanger CM, Dohi Y, Yang Z. Endothelium-derived contracting factors. Hypertension 1992; 19: 117-130.
5. Luscher TF, Noll G. Endothelium dysfunction in the coronary circulation. J Cardiovasc Pharmacol 1994; 24: 16S-26S.
6. Rubanyi GM, Vanhoutte PM. Hypoxia releases a vasoconstrictor substance from the canine vascular endothelium. J Physiol (Lond) 1985; 364: 45-56.
7. Yanagisawa M et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
8. Miller WL, Redfield MM, Burnett JC Jr. Integrated cardiac, renal and endocrine actions of endothelin. J Clin Invest 1989; 83: 317-320.
9. Lerman A, Hildebrand FL Jr, Aarhus LL, Burnett JC Jr. Endothelin has biologic actions at pathophysiologic concentration. Circulation 1991; 83: 1808-1814.
10. Margulies KB et al. Increased endothelin in experimental heart failure. Circulation 1990; 82: 2226-2230.
11. Lerman A et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325: 997-1001.
12. Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium-mediated coronary blood flow modulation in humans: effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 1993; 92: 652-662.
13. Ludmer PL et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315: 1046-1051.
14. Zeiher AM et al. Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. Circulation 1995; 91: 2345-2352.
15. Linder L, Kowsky W, Buhler FR, Luscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation 1992; 81: 1762-1767.
16. Tomanek RJ et al. Morphometry of canine coronary arteries, arterioles, and capillaries during hypertension and left ventricular hypertrophy. Circ Res 1986; 58: 38-46.
17. Luscher TF, Vanhoutte PM. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension 1986; 8: 344-348.
18. Treasure CB et al. Epicardial coronary artery responses to acetylcholine are impaired in hypertensive patients. Circ Res 1992; 72: 776-781.
19. Treasure CB et al. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 1993; 87: 86-93.
20. Frielingsdorf J et al. Normalization of abnormal coronary vasomotion by calcium antagonists in patients with hypertension. Circulation 1996; 93: 1380-1387.
21. Lerman A et al. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 1995; 92: 2426-2431.
22. Mancini GBJ et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996; 94: 258-265.
23. Yang Z et al. Different mobilization of calcium in endothelin-1 induced contractions in human arteries and veins: effects of calcium antagonists. J Cardiovasc Pharmacol 1990; 16: 654-660.
24. Chan DP, Keiser J, Burnett JC Jr. The modulating effects of converting enzyme inhibition upon the intrarenal action of endothelin. Am J Hypertens 1991; 4 (abstract): 15A-16A.
25. Clavell AL et al. Angiotensin-converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction. J Clin Invest 1996; 97: 1286-1292.
26. Cannan CR, Burnett JC Jr, Brandt RR, Lerman A. Endothelin at pathophysiological concentrations mediates coronary vasoconstriction via the endothelin-A receptor. Circulation 1995; 92: 3312-3317.
27. Lerman A, Sandok EK, Hildebrand FL Jr, Burnett JC Jr. Inhibition of endothelium-derived relaxing factor enhances endothelin-mediated vasoconstriction. Circulation 1992; 85: 1894-1898.
28. Pfeffer MA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669-677.